Pall T. Onundarson: The Fiix Test Team Was Awarded UNIVANTS 2025!
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, proudly reposted from Eduardo Freggiaro on LinkedIn:
”The Fiix test team was awarded UNIVANTS 2025 Team of Distinction and got to meet the UNIVANTS of HealthCare Excellence executives at the ADLM (previously AACC) 2025 in Chicago.
The prize is awarded by 7 important healthcare associations around the world.
These people see the potential of improved patient care through replacing the conventional monitoring method of warfarin and VKAs (PT-INR) with a new test that more accurately reflects the antithrombotic effect, reduces anticoagulation variability and enhances effectiveness of anticoagulation with the old drug class that everybody had written off and thought they knew all about…
But now clinical pharmacology needs some revision.
Fortunately, it is very easy to replace the PT-INR with the Fiix-NR: same instruments, same staff, mostly the same dosing protocols.
The Fiix test is CE marked in Europe, still for scientific use elsewhere, manufactured by Hart Biologicals Limited in England.”
Eduardo Freggiaro, President of FBA, Executive Board member of IFCC, shared an honoring post on LinkedIn:
”During the ADLM congress in Chicago I had the opportunity and honor to participate in this photo with the winners of the highest recognition of the UNIVANTS 2025 award.
Also present were previous winners, Abbott executives and the CEO of the ADLM.
Congratulations to Professor Pall T. Onundarson, M.D. and his team for the excellent work they have done.”
Stay updated on the emerging with Hemostasis Today.
-
May 27, 2026, 09:58Omid Seidizadeh: Take The EAHAD Survey on Access to Diagnosis and Treatment for VWD Europe
-
May 27, 2026, 09:51Richard Benjamin: RedeS Phase III Trial Reaches Major Milestone in Advancing Pathogen-Reduced RBCs for Transfusion
-
May 27, 2026, 04:47Daniel Torrent: The Overlooked Epidemic of Post-Thrombotic Syndrome
-
May 27, 2026, 04:45Graziella Pompei: Is Aspirin Still a Valid Alternative to Clopidogrel in PCI with DES Implantation?
-
May 27, 2026, 04:40Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
-
May 27, 2026, 04:29Francisco Chacón-Lozsán: High-Sensitivity Troponin and the Evolving Management of NSTEMI
-
May 27, 2026, 04:14Michael R. Jaff: HI-PEITHO Trial and NEWS Score Insights on Advances for Intermediate-Risk Pulmonary Embolism
-
May 26, 2026, 16:45Ashley George: Take the Leap for Thrombosis UK
-
May 26, 2026, 16:40Hamed Helisaz: Machine Learning for Detecting Missing Heart Medications